Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AVT05

Monoclonal antibody · developed by Alvotech Swiss

Phase 3 Most advanced trial (none active)

ALVO Developer

2 Registered trials

What is AVT05?

AVT05 is a recombinant human IgG1 kappa monoclonal antibody developed as a subcutaneous injection and supplied in pre-filled syringes. It is studied in healthy adult subjects and in rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Therapy area: Immunology
Developer: Alvotech Swiss AG (ALVO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05842213	Phase 3	Rheumatoid Arthritis	Completed	ALVO
NCT05632211	Phase 1	Healthy Adult Subjects	Completed	ALVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Adult SubjectsRheumatoid Arthritis

More from Alvotech Swiss

AVT03 Phase 3 AVT04 Phase 3 AVT06 Phase 3 AVT16 Phase 3 AVT29 Phase 3 AVT32-DRL_PB Phase 1 AVT80 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALVO page.

Follow ALVO, the company behind AVT05

See ALVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALVO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z